{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:43:56Z","timestamp":1772437436672,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Neuroendocrine tumours frequently metastasize to the liver. Although generally slowly progressing, hepatic metastases are the major cause of carcinoid syndrome and ultimately lead to liver dysfunction, cardiac insufficiency and finally death.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A literature review was performed to define the optimal treatment strategy and work-up in patients with neuroendocrine hepatic metastases. Based on this, an algorithm for the management of these patients was established.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Platelet serotonin and chromogranin A are useful biomarkers for detection and follow-up of neuroendocrine tumour. Helical computed tomography and somatostatin receptor scintigraphy are the most sensitive diagnostic modalities. Surgical debulking is an accepted approach for reducing hormonal symptoms and to establish better conditions for medical treatment, but is frequently impossible due to the extent of disease. A novel approach is the local ablation of tumour by thermal coagulation using therapies such as radiofrequency ablation (RFA) or laser induced thermotherapy (LITT). These techniques preserve normal liver tissue. There is a tendency to destroy metastases early in the course of disease, thereby postponing or eliminating the surgically untreatable stage. This can be combined with postoperative radioactive octreotide to eliminate small multiple metastases. In patients with extensive metastases who are not suitable for local destruction, systemic therapy by octreotide, <jats:sup>131<\/jats:sup>I-MIBG treatment or targeted chemo- and radiotherapy should be attempted. A final option for selective patients is orthotopic liver transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Treatment for patients with neuroendocrine hepatic metastases must be tailored for each individual patient. When local ablative therapies are used early in the course of the disease, the occurrence of carcinoid syndrome with end stage hepatic disease can be postponed or prevented.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7819-4-35","type":"journal-article","created":{"date-parts":[[2006,6,27]],"date-time":"2006-06-27T07:29:52Z","timestamp":1151393392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy"],"prefix":"10.1186","volume":"4","author":[{"given":"Liesbeth M","family":"Veenendaal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inne HM Borel","family":"Rinkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis JM","family":"Lips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"van Hillegersberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,6,26]]},"reference":[{"key":"190_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1677\/erc.0.0100427","volume":"10","author":"G Rindi","year":"2003","unstructured":"Rindi G, Bordi C: Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer. 2003, 10: 427-436. 10.1677\/erc.0.0100427.","journal-title":"Endocr Relat Cancer"},{"key":"190_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","volume":"1","author":"ED Williams","year":"1963","unstructured":"Williams ED, Sandler M: The classification of carcinoid tum ours. Lancet. 1963, 1: 238-239. 10.1016\/S0140-6736(63)90951-6.","journal-title":"Lancet"},{"key":"190_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-59655-1","volume-title":"International histological classification of endocrine tumours","author":"E Solcia","year":"2000","unstructured":"Solcia E, Kloppel G, Sobhin LH: Histological typing of endocrine tumours. International histological classification of endocrine tumours. 2000, Springer-Verlag: New York"},{"key":"190_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/1096-9098(200005)74:1<24::AID-JSO6>3.0.CO;2-V","volume":"74","author":"A Benevento","year":"2000","unstructured":"Benevento A, Boni L, Frediani L, Ferrari A, Dionigi R: Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol. 2000, 74: 24-29. 10.1002\/1096-9098(200005)74:1<24::AID-JSO6>3.0.CO;2-V.","journal-title":"J Surg Oncol"},{"key":"190_CR5","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4","volume":"36","author":"JD Godwin","year":"1975","unstructured":"Godwin JD: Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975, 36: 560-569.","journal-title":"Cancer"},{"key":"190_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/bjs.1800810725","volume":"81","author":"EW McDermott","year":"1994","unstructured":"McDermott EW, Guduric B, Brennan MF: Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg. 1994, 81: 1007-1009.","journal-title":"Br J Surg"},{"key":"190_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/archsurg.1982.01380290176031","volume":"117","author":"J Zeitels","year":"1982","unstructured":"Zeitels J, Naunheim K, Kaplan EL, Straus F: Carcinoid tumors: a 37-year experience. Arch Surg. 1982, 117: 732-737.","journal-title":"Arch Surg"},{"key":"190_CR8","doi-asserted-by":"crossref","unstructured":"Oates JA: The carcinoid syndrome. N Engl J Med. 315: 702-704. 11-9-1986","DOI":"10.1056\/NEJM198609113151109"},{"key":"190_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","volume":"190","author":"RS Chamberlain","year":"2000","unstructured":"Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, Blumgart LH: Hepatic neuroendocrine metastases: does intervention alter outcomes?. J Am Coll Surg. 2000, 190: 432-445. 10.1016\/S1072-7515(00)00222-2.","journal-title":"J Am Coll Surg"},{"key":"190_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1072-7515(98)00099-4","volume":"187","author":"H Chen","year":"1998","unstructured":"Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?. J Am Coll Surg. 1998, 187: 88-92. 10.1016\/S1072-7515(98)00099-4.","journal-title":"J Am Coll Surg"},{"key":"190_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/00365529109111236","volume":"188","author":"MJ Farthing","year":"1991","unstructured":"Farthing MJ: 5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists. Scand J Gastroenterol Suppl. 1991, 188: 92-100.","journal-title":"Scand J Gastroenterol Suppl"},{"key":"190_CR12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/clinchem\/40.1.86","volume":"40","author":"IP Kema","year":"1994","unstructured":"Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA: Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clin Chem. 1994, 40: 86-95.","journal-title":"Clin Chem"},{"key":"190_CR13","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/clinchem\/46.10.1588","volume":"46","author":"WG Meijer","year":"2000","unstructured":"Meijer WG, Kema IP, Volmer M, Willemse PH, de Vries EG: Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem. 2000, 46: 1588-1596.","journal-title":"Clin Chem"},{"key":"190_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/000456320203900605","volume":"39","author":"RS Carling","year":"2002","unstructured":"Carling RS, Degg TJ, Allen KR, Bax ND, Barth JH: Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease. Ann Clin Biochem. 2002, 39: 577-582. 10.1258\/000456302760413351.","journal-title":"Ann Clin Biochem"},{"key":"190_CR15","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/clinchem\/38.9.1730","volume":"38","author":"IP Kema","year":"1992","unstructured":"Kema IP, Schellings AM, Meiborg G, Hoppenbrouwers CJ, Muskiet FA: Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites. Clin Chem. 1992, 38: 1730-1736.","journal-title":"Clin Chem"},{"key":"190_CR16","doi-asserted-by":"crossref","unstructured":"Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 86: 858-865. 10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8. 1-9-1999","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8"},{"key":"190_CR17","doi-asserted-by":"crossref","unstructured":"Hutton JC, Davidson HW, Peshavaria M: Proteolytic processing of chromogranin A in purified insulin granules. Formation of a 20 kDa N-terminal fragment (betagranin) by the concerted action of a Ca2+-dependent endopeptidase and carboxypeptidase H (EC 3.4.17.10). Biochem J. 244: 457-464. 1-6-1987","DOI":"10.1042\/bj2440457"},{"key":"190_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1515\/CCLM.1998.147","volume":"36","author":"RA Pirker","year":"1998","unstructured":"Pirker RA, Pont J, Pohnl R, Schutz W, Griesmacher A, Muller MM: Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clin Chem Lab Med. 1998, 36: 837-840. 10.1515\/CCLM.1998.147.","journal-title":"Clin Chem Lab Med"},{"key":"190_CR19","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1210\/jc.82.8.2622","volume":"82","author":"FR Nobels","year":"1997","unstructured":"Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997, 82: 2622-2628. 10.1210\/jc.82.8.2622.","journal-title":"J Clin Endocrinol Metab"},{"key":"190_CR20","doi-asserted-by":"crossref","unstructured":"Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT: Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 125: 26-34. 1-7-1996","DOI":"10.7326\/0003-4819-125-1-199607010-00005"},{"key":"190_CR21","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1007\/s002590050314","volume":"25","author":"A Chiti","year":"1998","unstructured":"Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, van Graafeiland BJ, Monetti N, Bombardieri E: Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med. 1998, 25: 1396-1403. 10.1007\/s002590050314.","journal-title":"Eur J Nucl Med"},{"key":"190_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1148\/radiology.171.3.2655004","volume":"171","author":"H Frucht","year":"1989","unstructured":"Frucht H, Doppman JL, Norton JA, Miller DL, Dwyer AJ, Frank JA, Vinayek R, Maton PN, Jensen RT: Gastrinomas: comparison of MR imaging with CT, angiography, and US. Radiology. 1989, 171: 713-717.","journal-title":"Radiology"},{"key":"190_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/gast.1997.v112.pm9024287","volume":"112","author":"B Termanini","year":"1997","unstructured":"Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff VE, Jensen RT: Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology. 1997, 112: 335-347. 10.1053\/gast.1997.v112.pm9024287.","journal-title":"Gastroenterology"},{"key":"190_CR24","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/annonc\/mdg160","volume":"14","author":"F Panzuto","year":"2003","unstructured":"Panzuto F, Falconi M, Nasoni S, Angeletti S, Moretti A, Bezzi M, Gualdi G, Polettini E, Sciuto R, Festa A, Scopinaro F, Corleto VD, Bordi C, Pederzoli P, Delle FG: Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy. Ann Oncol. 2003, 14: 586-591. 10.1093\/annonc\/mdg160.","journal-title":"Ann Oncol"},{"key":"190_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/BF00169802","volume":"20","author":"DJ Kwekkeboom","year":"1993","unstructured":"Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PP, Lamberts SW: Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med. 1993, 20: 283-292. 10.1007\/BF00169802.","journal-title":"Eur J Nucl Med"},{"key":"190_CR26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/107327480200900111","volume":"9","author":"FG Que","year":"2002","unstructured":"Que FG, Sarmiento JM, Nagorney DM: Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control. 2002, 9: 67-79.","journal-title":"Cancer Control"},{"key":"190_CR27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3748\/wjg.v9.i2.193","volume":"9","author":"LX Liu","year":"2003","unstructured":"Liu LX, Zhang WH, Jiang HC: Current treatment for liver metastases from colorectal cancer. World J Gastroenterol. 2003, 9: 193-200.","journal-title":"World J Gastroenterol"},{"key":"190_CR28","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0002-9610(01)00813-3","volume":"182","author":"SL Wong","year":"2001","unstructured":"Wong SL, Edwards MJ, Chao C, Simpson D, McMasters KM: Radiofrequency ablation for unresectable hepatic tumors. Am J Surg. 2001, 182: 552-557. 10.1016\/S0002-9610(01)00813-3.","journal-title":"Am J Surg"},{"key":"190_CR29","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00268-002-6629-5","volume":"26","author":"E Berber","year":"2002","unstructured":"Berber E, Flesher N, Siperstein AE: Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002, 26: 985-990. 10.1007\/s00268-002-6629-5.","journal-title":"World J Surg"},{"key":"190_CR30","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00268-002-6663-3","volume":"26","author":"P Hellman","year":"2002","unstructured":"Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A: Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg. 2002, 26: 1052-1056. 10.1007\/s00268-002-6663-3.","journal-title":"World J Surg"},{"key":"190_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1006\/jsre.2000.5988","volume":"95","author":"FJ Wessels","year":"2001","unstructured":"Wessels FJ, Schell SR: Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res. 2001, 95: 8-12. 10.1006\/jsre.2000.5988.","journal-title":"J Surg Res"},{"key":"190_CR32","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0039-6060(97)90221-X","volume":"122","author":"AE Siperstein","year":"1997","unstructured":"Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A: Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery. 1997, 122: 1147-1154. 10.1016\/S0039-6060(97)90221-X.","journal-title":"Surgery"},{"key":"190_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1477-7819-3-75","volume":"3","author":"V Meij","year":"2005","unstructured":"Meij V, Zuetenhorst JM, van Hillegersberg R, Kroger R, Prevoo W, van Coevorden F, Taal BG: Local treatment in unresectable hepatic metastases of carcinoid tumors: Experiences with hepatic artery embolization and radiofrequency ablation. World J Surg Oncol. 2005, 3: 75-10.1186\/1477-7819-3-75.","journal-title":"World J Surg Oncol"},{"key":"190_CR34","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2214\/ajr.175.6.1751619","volume":"175","author":"T de Baere","year":"2000","unstructured":"de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, Boige V, Lassau N, Marteau V, Lasser P, Roche A: Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol. 2000, 175: 1619-1625.","journal-title":"AJR Am J Roentgenol"},{"key":"190_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/pho.2006.24.3","volume":"24","author":"LM Veenendaal","year":"2006","unstructured":"Veenendaal LM, de Jager A, Stapper G, Borel Rinkes IHM, van Hillegersberg R: Multiple fiber laser-induced thermotherapy for ablation of large intrahepatic tumors. Photomed Laser Surg. 2006, 24: 3-9. 10.1089\/pho.2006.24.3.","journal-title":"Photomed Laser Surg"},{"key":"190_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00042737-200601000-00016","volume":"18","author":"LM Veenendaal","year":"2006","unstructured":"Veenendaal LM, Borel Rinkes IHM, van Hillegersberg R: Multipolar radiofrequency ablation of large hepatic metastases of endocrine tumours. Eur J Gastroenterol Hepatol. 2006, 18: 89-92. 10.1097\/00042737-200601000-00016.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"190_CR37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2214\/ajr.181.4.1811005","volume":"181","author":"AR Henn","year":"2003","unstructured":"Henn AR, Levine EA, McNulty W, Zagoria RJ: Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol. 2003, 181: 1005-1010.","journal-title":"AJR Am J Roentgenol"},{"key":"190_CR38","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/01.sla.0000118373.31781.f2","volume":"239","author":"SA Curley","year":"2004","unstructured":"Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, Scaife C, Raut C, Wolff R, Choi H, Loyer E, Vallone P, Fiore F, Scordino F, De RV, Orlando R, Pignata S, Daniele B, Izzo F: Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg. 2004, 239: 450-458. 10.1097\/01.sla.0000118373.31781.f2.","journal-title":"Ann Surg"},{"key":"190_CR39","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/01.sla.0000118565.21298.0a","volume":"239","author":"RT Poon","year":"2004","unstructured":"Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST, Wong J: Learning curve for radiofrequency ablation of liver tumors: prospective analysis of initial 100 patients in a tertiary institution. Ann Surg. 2004, 239: 441-449. 10.1097\/01.sla.0000118565.21298.0a.","journal-title":"Ann Surg"},{"key":"190_CR40","first-page":"830","volume":"51","author":"M Wettstein","year":"2004","unstructured":"Wettstein M, Vogt C, Cohnen M, Brill N, Kurz AK, Modder U, Haussinger D: Serotonin release during percutaneous radiofrequency ablation in a patient with symptomatic liver metastases of a neuroendocrine tumor. Hepatogastroenterology. 2004, 51: 830-832.","journal-title":"Hepatogastroenterology"},{"key":"190_CR41","first-page":"349","volume":"61","author":"RR Warner","year":"1994","unstructured":"Warner RR, Mani S, Profeta J, Grunstein E: Octreotide treatment of carcinoid hypertensive crisis. Mt Sinai J Med. 1994, 61: 349-355.","journal-title":"Mt Sinai J Med"},{"key":"190_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/bja\/72.3.335","volume":"72","author":"GR Veall","year":"1994","unstructured":"Veall GR, Peacock JE, Bax ND, Reilly CS: Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth. 1994, 72: 335-341.","journal-title":"Br J Anaesth"},{"key":"190_CR43","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/bja\/87.3.447","volume":"87","author":"MA Kinney","year":"2001","unstructured":"Kinney MA, Warner ME, Nagorney DM, Rubin J, Schroeder DR, Maxson PM, Warner MA: Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth. 2001, 87: 447-452. 10.1093\/bja\/87.3.447.","journal-title":"Br J Anaesth"},{"key":"190_CR44","first-page":"1029","volume":"76","author":"A Roche","year":"1989","unstructured":"Roche A: [Hepatic chemo-embolization]. Bull Cancer. 1989, 76: 1029-1037.","journal-title":"Bull Cancer"},{"key":"190_CR45","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S1091-255X(02)00044-6","volume":"6","author":"SR Schell","year":"2002","unstructured":"Schell SR, Camp ER, Caridi JG, Hawkins IF: Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg. 2002, 6: 664-670. 10.1016\/S1091-255X(02)00044-6.","journal-title":"J Gastrointest Surg"},{"key":"190_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2214\/ajr.147.1.149","volume":"147","author":"CH Carrasco","year":"1986","unstructured":"Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S: The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986, 147: 149-154.","journal-title":"AJR Am J Roentgenol"},{"key":"190_CR47","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2214\/ajr.170.2.9456942","volume":"170","author":"E Diamandidou","year":"1998","unstructured":"Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, Lawrence DD, Wallace S: Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. AJR Am J Roentgenol. 1998, 170: 339-344.","journal-title":"AJR Am J Roentgenol"},{"key":"190_CR48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1677\/erc.0.0100463","volume":"10","author":"D O'Toole","year":"2003","unstructured":"O'Toole D, Maire F, Ruszniewski P: Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer. 2003, 10: 463-468. 10.1677\/erc.0.0100463.","journal-title":"Endocr Relat Cancer"},{"key":"190_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000074522","volume":"68","author":"O Kress","year":"2003","unstructured":"Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H: Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors \u2013 a retrospective single-center analysis. Digestion. 2003, 68: 94-101. 10.1159\/000074522.","journal-title":"Digestion"},{"key":"190_CR50","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3109\/00365529108998580","volume":"26","author":"F Kolmannskog","year":"1991","unstructured":"Kolmannskog F, Kolbenstvedt AN, Schrumpf E, Hanssen LE: Side effects and complications after hepatic artery embolization in the carcinoid syndrome. Scand J Gastroenterol. 1991, 26: 557-562.","journal-title":"Scand J Gastroenterol"},{"key":"190_CR51","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1051-0443(99)70055-2","volume":"10","author":"KT Brown","year":"1999","unstructured":"Brown KT, Koh BY, Brody LA, Getrajdman GI, Susman J, Fong Y, Blumgart LH: Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol. 1999, 10: 397-403.","journal-title":"J Vasc Interv Radiol"},{"key":"190_CR52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/00001813-199410000-00001","volume":"5","author":"K Oberg","year":"1994","unstructured":"Oberg K: Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs. 1994, 5: 503-519.","journal-title":"Anticancer Drugs"},{"key":"190_CR53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2796.1995.tb01175.x","volume":"237","author":"MB Jacobsen","year":"1995","unstructured":"Jacobsen MB, Hanssen LE: Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med. 1995, 237: 269-275.","journal-title":"J Intern Med"},{"key":"190_CR54","first-page":"1743","volume":"39","author":"EM Prvulovich","year":"1998","unstructured":"Prvulovich EM, Stein RC, Bomanji JB, Ledermann JA, Taylor I, Ell PJ: Iodine-131-MIBG therapy of a patient with carcinoid liver metastases. J Nucl Med. 1998, 39: 1743-1745.","journal-title":"J Nucl Med"},{"key":"190_CR55","doi-asserted-by":"crossref","unstructured":"Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW, Tyler DS, Olson JA: Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Cancer. 101: 1987-1993. 10.1002\/cncr.20592. 28-9-2004","DOI":"10.1002\/cncr.20592"},{"issue":"Suppl 1","key":"190_CR56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1365-2141.1991.tb08125.x","volume":"79","author":"K Oberg","year":"1991","unstructured":"Oberg K, Eriksson B: The role of interferons in the management of carcinoid tumours. Br J Haematol. 1991, 79 (Suppl 1): 74-77.","journal-title":"Br J Haematol"},{"key":"190_CR57","doi-asserted-by":"crossref","unstructured":"Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors \u2013 the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 21: 2689-2696. 10.1200\/JCO.2003.12.142. 15-7-2003","DOI":"10.1200\/JCO.2003.12.142"},{"key":"190_CR58","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ctrv.2003.07.002","volume":"29","author":"UF Pape","year":"2003","unstructured":"Pape UF, Wiedenmann B: Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours. Cancer Treat Rev. 2003, 29: 565-569. 10.1016\/j.ctrv.2003.07.002.","journal-title":"Cancer Treat Rev"},{"key":"190_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/eje.0.1410001","volume":"141","author":"AV Schally","year":"1999","unstructured":"Schally AV, Nagy A: Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol. 1999, 141: 1-14. 10.1530\/eje.0.1410001.","journal-title":"Eur J Endocrinol"},{"key":"190_CR60","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1358\/dof.2001.026.03.858706","volume":"26","author":"A Nagy","year":"2001","unstructured":"Nagy A, Schally AV: Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers. Drugs Future. 2001, 26: 261-270. 10.1358\/dof.2001.026.03.858706.","journal-title":"Drugs Future"},{"key":"190_CR61","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/snuc.2002.31027","volume":"32","author":"M De Jong","year":"2002","unstructured":"De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP: Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002, 32: 133-140. 10.1053\/snuc.2002.31027.","journal-title":"Semin Nucl Med"},{"key":"190_CR62","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1210\/jc.2004-2290","volume":"90","author":"MG Lam","year":"2005","unstructured":"Lam MG, Lips CJ, Jager PL, Dullaart RP, Lentjes EG, van Rijk PP, de Klerk JM: Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma. J Clin Endocrinol Metab. 2005, 90: 5888-5895. 10.1210\/jc.2004-2290.","journal-title":"J Clin Endocrinol Metab"},{"key":"190_CR63","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.gassur.2003.11.010","volume":"8","author":"S Florman","year":"2004","unstructured":"Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, Fishbein T, Emre S, Miller C, Schwartz M: Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004, 8: 208-212. 10.1016\/j.gassur.2003.11.010.","journal-title":"J Gastrointest Surg"},{"key":"190_CR64","first-page":"726","volume":"110","author":"I Penn","year":"1991","unstructured":"Penn I: Hepatic transplantation for primary and metastatic cancers of the liver. Surgery. 1991, 110: 726-734.","journal-title":"Surgery"},{"key":"190_CR65","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/00000658-199704000-00003","volume":"225","author":"YP Le Treut","year":"1997","unstructured":"Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, Hannoun L, Benhamou G, Launois B, Boillot O, Domergue J, Bismuth H: Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg. 1997, 225: 355-364. 10.1097\/00000658-199704000-00003.","journal-title":"Ann Surg"},{"key":"190_CR66","doi-asserted-by":"crossref","unstructured":"Lehnert T: Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 66: 1307-1312. 27-11-1998","DOI":"10.1097\/00007890-199811270-00007"},{"key":"190_CR67","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1196\/annals.1294.029","volume":"1014","author":"H Ahlman","year":"2004","unstructured":"Ahlman H, Friman S, Cahlin C, Nilsson O, Jansson S, Wangberg B, Olausson M: Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann N Y Acad Sci. 2004, 1014: 265-269. 10.1196\/annals.1294.029.","journal-title":"Ann N Y Acad Sci"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7819-4-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:22:16Z","timestamp":1630452136000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/1477-7819-4-35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,26]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["190"],"URL":"https:\/\/doi.org\/10.1186\/1477-7819-4-35","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,26]]},"assertion":[{"value":"7 April 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2006","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"35"}}